Search for content, post, videos
Advertisement

Center for Translational Research launches CTC Netherlands

Center for Translational Research (CTR) expands its portfolio of life science service companies through the establishment of CTC Netherlands BV.

CTC Netherlands BV is CTR group’s first company outside of Sweden. The new company will operate a clinical research unit that specializes in early phase patient research and healthy volunteer studies that require invasive procedures.

The new company will operate a clinical research unit that specializes in early phase patient research and healthy volunteer studies that require invasive procedures.”

“The strategic importance of this first ‘CTR footprint’ outside Sweden can’t be underestimated,” says Dr Karin Meyer, the CEO of CTR. “The Netherlands have a strong scientific foundation within translational research and attractive processes for managing early clinical trials. That, combined with the exceptionally senior team of co-founders of CTC NL, will enable the CTR group to offer early clinical development capabilities in an efficient multinational setting to our current and future customers.”

The founders of CTC NL are CEO Dr. Wim Tamminga, COO Dr. Petra Schuilenga-Hut, and CPO Mariska Beukers-Reuvers, MSc.

Located at the campus of the University Medical Center Groningen

The new clinic will be located at the campus of the University Medical Center Groningen (UMCG) and will have 12 beds.

“Early-phase clinical research often focuses on large studies in healthy volunteers, but increasing efforts are being made to integrate early phase studies in patients. This will accelerate the development of medicines, which is good for the patient the sponsor, and society at large. However, the distinct organizational and operational requirements of early-phase patient studies, compared to those of healthy volunteer studies, are very complex and challenging for many. Our new specialized clinical research unit with its dedicated team of experts addresses these particular needs effectively, offering comprehensive support for early phase patient studies,” says Dr. Petra Schuilenga-Hut.

CTC NL will operate in close collaboration with the Swedish team.”

While the new company is a separate legal entity, CTC NL will function as a part of the site network structure within CTC Clinical Trials Consultants AB (CTC). Headquartered in Uppsala, CTC is a full-service CRO with its own site network consisting of six clinics across Sweden, and is the largest company within the CTR group. CTC NL will operate in close collaboration with the Swedish team.

The new company will open its doors in April 2024.

Photo of the three founders of CTC Netherlands outside the new clinic in Groningen, February 2024. From the left: COO Dr. Petra Schuilenga-Hut, CEO Dr. Wim Tamminga, and CPO Mariska Beukers-Reuvers. Credit: CTC Netherlands